An observational study in Delirium - Postoperative, Delirium Prevention and Dexmedetomidine, sponsored by Peter Gaarsdal Uhrbrand. Recruiting at 1 site in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Peter Gaarsdal Uhrbrand · Observational
Postoperative delirium is common after hip fracture surgery and is associated with delayed recovery and serious postoperative complications. Patients with hip fracture are often elderly, acutely admitted, in pain, and have multiple comorbidities, all of which increase the risk of delirium.
This study evaluates whether implementation of intraoperative dexmedetomidine prophylaxis reduces postoperative delirium in patients undergoing hip fracture surgery. The study will compare patients treated before and after implementation of dexmedetomidine prophylaxis.
788 studies on the registry are indexed under Emergence Delirium; 250 are open to participants now.
This study's planned enrollment of 242 is above the median of 154 across 288 observational studies indexed under Emergence Delirium.
Browse Emergence Delirium studies →This is the only study on the registry with Peter Gaarsdal Uhrbrand as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Study participants will be selected from patients undergoing surgery for hip fracture at the Department of Orthopedics, Aarhus University Hospital, Denmark. The study population will include patients aged 65 years or older undergoing operative treatment in either general or spinal anesthesia. Patients will be identified consecutively during the predefined pre-implementation and post-implementation study periods. In the post-implementation period, eligible patients will receive perioperative dexmedetomidine prophylaxis unless contraindications or other clinical reasons for omission are present. Patients with severe liver failure, acute neurological conditions, or second- or third-degree atrioventricular block without a pacemaker will not receive dexmedetomidine
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients undergoing hip fracture surgery before implementation of intraoperative dexmedetomidine prophylaxis.
Patients undergoing hip fracture surgery after implementation of intraoperative dexmedetomidine prophylaxis. Dexmedetomidine prophylaxis is initiated after induction of general anesthesia or after spinal anesthesia has been established. Patients receive dexmedetomidine bolus 0.5 µg/kg ideal body weight followed by infusion 0.5 µg/kg/hour. The infusion is discontinued at the end of surgery.
Any postoperative delirium within the first 3 days after surgery
The proportion of patients with at least one positive CAM-score on postoperative day 1-3 (yes/no).
Time frame: Postoperative day 1-3
Any postoperative delirium within the first 7 days after surgery
The proportion of patients with at least one positive CAM-score on postoperative day 1-7 (yes/no).
Time frame: Postoperative day 1-7
Maximum severity of postoperative delirium
Maximum severity of postoperative delirium based on CAM score (mild, moderate, severe)
Time frame: Postoperative day 1-7
Postoperative pain in the PACU
NRS (0-10) at rest and during mobilisation in the PACU
Time frame: PACU stay
Postoperative opioid use in the PACU
Cumulative opioid consumption during the PACU stay (oral morphine milligram equivalents)
Time frame: PACU stay
Need for antipsychotic medication
Any new use of haloperidol, olanzapine, risperidone, quetiapine or similar medication (yes/no)
Time frame: Postoperative day 1-7
Intraoperative treatment with moderate-dose vasopressors
Intraoperative dose of norepinephrine \> 0,1ug/kg/min (yes/no)
Time frame: Intraoperative period
Perioperative treatment of bradycardia
Perioperative treatment of bradycardia with atropin (yes/no)
Time frame: Intraoperative period and PACU stay
Postoperative vasopressor treatment
Any vasopressor use in the PACU (yes/no)
Time frame: PACU stay
Length of stay in the PACU
Length of stay in the PACU (min)
Time frame: PACU stay
Plan to share: No — The project is not approved for sharing individual participant data.
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Mar 2027, 5 months after the start.
Of 187 non-industry observational studies under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 5 months is below that.
Counting every sponsor, half of 188 studies reached it within 20 months; a quarter within 10 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.